Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(8)
DRUG(7)
BIOLOGICAL(1)
PEGASYS
2 trials
phase_1phase_3
ronald-hoffman, john-mascarenhas
Ruxolitinib
2 trials
phase_1_2phase_2
john-mascarenhas
Aspirin
2 trials
phase_2phase_3
ronald-hoffman
monoclonal antibody to TGF-beta
1 trial
phase_1
john-mascarenhas
Enasidenib
1 trial
phase_2
john-mascarenhas
AVID200
1 trial
phase_1
john-mascarenhas
Blood specimen
1 trial
icahn-school-of-medicine-at-mount-sinai
RG7388
1 trial
phase_1
john-mascarenhas

+5 more interventions

13 unique interventions3 categories

Analytics

Trial Phases

Phase 16
Phase 25
Phase 31

Trial Status

Completed6
Terminated1
Other3

Role Distribution

Principal Investigator5
Other Roles5
PI Rate50%

Activity Timeline

Clinical Trials (10)

NCT04281498Phase 2Completed
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
StudychairStart date: 2021-01-14
NCT03895112Phase 1Completed
MPN-RC 118 AVID200 in Myelofibrosis
Post ET MFPost PV MFPost-essential Thrombocythemia Myelofibrosis+2 more
StudydirectorStart date: 2019-02-15
NCT00668421Phase 1/2Unknown
CEP-701 (Lestaurtinib) in Myelofibrosis
Essential ThrombocythemiaMyelofibrosisPolycythemia Vera
Principalinvestigator
NCT00940784Phase 2Withdrawn
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera
Polycythemia Vera
Principalinvestigator
NCT01259856Phase 3Completed
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Studychair
NCT01291784Phase 1Terminated
Anti-TGF-beta Therapy in Patients With Myelofibrosis
MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-essential Thrombocythemia Related Myelofibrosis+1 more
Studychair
NCT01298934Phase 1/2Unknown
LBH589 (Panobinostat) for the Treatment of Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related MyelofibrosisPrimary Myelofibrosis
Principalinvestigator
NCT01970930Completed
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Essential ThrombocythemiaPolycythemia Vera
Principalinvestigator
NCT02076191Phase 1/2Completed
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML
Myeloproliferative Neoplasms
Principalinvestigator
NCT02407080Phase 1Completed
Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia
Essential ThrombocythemiaPolycythemia Vera
Studychair

Research Network

Collaboration Network

26 collaborators·38 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

John Mascarenhas, MD

Icahn School of Medicine at Mount Sinai

Very Similar
16 trials

Shared therapeutic areas:

Primary MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPolycythemia Vera+12 more

Worked with same sponsors:

Celgene CorporationFormation Biologics+12 more
Collaborated on 6 trials
Similarity Score174%

Ruben Mesa, MD

Mays Cancer Center at UT Health

Very Similar
2 trials

Shared therapeutic areas:

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation+5 more

Worked with same sponsors:

Celgene CorporationFormation Biologics+6 more
Collaborated on 2 trials
Similarity Score88%

Ruben Mesa, MD

Mayo Clinic

Similar
2 trials

Shared therapeutic areas:

Thrombocythemia, EssentialHigh Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera+2 more

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score54%

Michal Bar-Natan, MD

Icahn School of Medicine at Mount Sinai

Moderately Similar
1 trials

Shared therapeutic areas:

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation

Worked with same sponsors:

Celgene CorporationIncyte Corporation+4 more
Collaborated on 1 trial
Similarity Score34%

Jean-Jacques Kiladjian, MD

Hopitaux de Paris

Related
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score24%

Mary Frances McMullin, MD

Belfast Health and Social Care Trust

Related
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score24%

Claire Harrison, MD

Guy's and St Thomas' NHS Foundation Trust

Related
1 trials

Shared therapeutic areas:

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera

Worked with same sponsors:

Myeloproliferative Disorders-Research ConsortiumNational Cancer Institute (NCI)+2 more
Collaborated on 1 trial
Similarity Score24%

Brenda Sandmaier

Fred Hutch/University of Washington Cancer Consortium

Related
7 trials

Shared therapeutic areas:

Thrombocythemia, EssentialPolycythemia VeraPolycythemia Vera, Post-Polycythemic Myelofibrosis Phase+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Ryotaro Nakamura

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Primary MyelofibrosisThrombocythemia, EssentialPolycythemia Vera

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Will Savage, MD PhD

Disc Medicine

Related
6 trials

Shared therapeutic areas:

Primary MyelofibrosisPolycythemia VeraPost-Essential Thrombocythemia Myelofibrosis
Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (10)

Showing 10 of 10 trials

NCT04281498Phase 2StudyChair

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Accelerated/Blast-phase Myeloproliferative NeoplasmChronic-phase MyelofibrosisIDH2 Mutation
Completed
NCT03895112Phase 1StudyDirector

MPN-RC 118 AVID200 in Myelofibrosis

Post ET MFPost PV MFPost-essential Thrombocythemia Myelofibrosis+2 more
Completed
NCT00668421Phase 1/2PrincipalInvestigator

CEP-701 (Lestaurtinib) in Myelofibrosis

Essential ThrombocythemiaMyelofibrosisPolycythemia Vera
Unknown
NCT00940784Phase 2PrincipalInvestigator

Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

Polycythemia Vera
Withdrawn
NCT01259856Phase 3StudyChair

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Essential ThrombocythemiaHigh Risk Polycythemia Vera
Completed
NCT01291784Phase 1StudyChair

Anti-TGF-beta Therapy in Patients With Myelofibrosis

MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-essential Thrombocythemia Related Myelofibrosis+1 more
Terminated
NCT01298934Phase 1/2PrincipalInvestigator

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related MyelofibrosisPrimary Myelofibrosis
Unknown
NCT01970930PrincipalInvestigator

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

Essential ThrombocythemiaPolycythemia Vera
Completed
NCT02076191Phase 1/2PrincipalInvestigator

Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

Myeloproliferative Neoplasms
Completed
NCT02407080Phase 1StudyChair

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Essential ThrombocythemiaPolycythemia Vera
Completed

All 10 trials loaded